Search

everythinglearnresearchcommunity

for

Search:↓

Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

The user shared their 5-year progress using finasteride and topical minoxidil for hair growth, noting initial success but recent thinning and side effects. They plan to switch to dutasteride and oral minoxidil, addressing low iron levels and monitoring potential side effects.

A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A 25-year-old is using a nightly routine of topical finasteride 0.3% and minoxidil 6%, along with a derma roller and Nizoral shampoo, to address crown hair loss. The user reports no side effects and noticeable improvement over 2.5 months.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

The conversation is about someone's progress after using 2.5mg of oral finasteride and minoxidil for hair loss over six months. Commenters are congratulating the individual on their successful hair regrowth.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

A user who experienced significant hair growth after using finasteride and minoxidil foam for five and six months respectively, with the addition of a hair transplant.

User shared progress after 5 months of using finasteride, minoxidil foam, and weekly derma rolling. Positive feedback highlights increased hair count and thickness.

A user had a 2250 graft hair transplant using both FUT and FUE methods, and is currently using finasteride, minoxidil, multivitamins, and biotin. Opinions vary on the effectiveness and appearance of the procedure, with some suggesting additional treatments or considering alternative options like shaving or using a hair system.

OP has been using alfatradiol and a mix of rosemary, peppermint, and jojoba oils for hair loss, with inconsistent dermapen sessions. They plan to add topical finasteride at 0.025% later.

A user reported impressive hair regrowth after 5 months using finasteride 1mg daily, topical minoxidil 5% twice a day, and microneedling. They initially experienced shedding but now have minimal hair loss and no sexual side effects.

The user is using oral finasteride and minoxidil for hair loss but reduced the dosage due to side effects like lightheadedness and weakness. They are also taking vitamins and natural DHT blockers.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

The user experienced significant hair improvement using 1mg finasteride and 2.5mg oral minoxidil daily, with most gains attributed to finasteride. They also stopped using topical treatments due to scalp psoriasis and reported no major side effects.

The user shared their 4.5-month progress using oral finasteride, topical minoxidil, and oral dutasteride, along with biotin, vitamin D, saw palmetto, and multivitamins. They use a combination of finasteride and dutasteride weekly, with micro-stamping, to address hair loss.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.